ENVALITH
タカラバイオ株式会社 logo

TAKARA BIO INC.

4974・Prime Market・Chemicals

Official website
タカラバイオ株式会社 logo
TAKARA BIO INC.4974

Business

Starting from the launch of restriction enzymes in 1979, TAKARA BIO INC. is a biotechnology-focused company operating four businesses: Reagents, Instruments, Contract Services (CDMO), and Gene Therapy. As an operating subsidiary of TAKARA HOLDINGS INC. (holding 60.93% of voting rights), it has built a global structure with 8 subsidiaries in Japan, the United States, Europe, China, South Korea, and India. Its main customers are universities, public research institutions, pharmaceutical companies, and testing companies, and it has expanded its business scope from research support to industrial applications and clinical development support. Net sales for FY2025 were ¥45,039 million.

Business Model

Research Reagents account for approximately 71% of net sales (¥31,995 million), followed by contract services (¥8,113 million), Gene Therapy (¥3,757 million), and Scientific Instruments (¥1,172 million). Research Reagents comprise a product lineup based on proprietary genetic engineering technology, offered through distributors or direct sales, while CDMO Services receive orders for GCTP/GMP-compliant manufacturing of regenerative medicine-related products from pharmaceutical companies and others. In Gene Therapy, the company sells Ancillary Materials such as RetroNectin® while also aiming to license out its proprietary drug discovery platform technology.

Company Strengths

With over 45 years of technological accumulation since launching Japan's first domestically produced restriction enzyme, the company holds patents in Japan, the US, Europe, China, and Korea for proprietary technologies including siTCR®, JAK/STAT, CAR, and CereAAV™. The RetroNectin® method (developed in 1995) serves as an industry-standard auxiliary agent for CAR-T cell manufacturing, driving a 17.1% increase in Gene Therapy category sales.

The company operates 8 subsidiaries including Takara Bio USA (US), Takara Bio Europe S.A.S. (France), and Dalian TaKaRa Biotechnology (China). In FY2025, European sales reached ¥4,187 million (vs. ¥3,895 million in the prior period) and Japan sales reached ¥8,493 million (vs. ¥8,107 million in the prior period), achieving multi-polar growth. The acquisition of Curio Bioscience (January 2025) also marked entry into the spatial transcriptome analysis field.

Against total assets of ¥125,334 million at the end of FY2025, total liabilities were only ¥9,485 million, with net assets of ¥115,849 million, resulting in an equity ratio of approximately 92%. The company holds cash and cash equivalents of ¥27,036 million, giving it the financial strength to fund capital expenditures (¥10,106 million in FY2025), M&A, and R&D (¥6,897 million) from its own funds without relying on interest-bearing debt.

ENVALITH's Perspective

In FY2026 (ending March 2026), net sales were ¥40,318 million (down 10.5% year on year), operating loss was ¥4,688 million (versus operating income of ¥2,263 million in the prior period), and net loss attributable to owners of parent was ¥9,599 million, marking a further deepening of the earnings slump following the fading of COVID-related demand. All categories posted revenue declines: Research Reagents (down 8.7% year on year), Scientific Instruments (down 23.5%), Services/CDMO (down 10.1%), and Gene Therapy (down 22.0%). External factors included a global reduction in life science research budgets, significant cuts to U.S. government research grants, and intensifying competition in China.

An impairment loss of ¥3,876 million was recorded on idle CDMO manufacturing facilities and related assets, bringing total extraordinary losses to ¥4,319 million, and pushing loss before income taxes to ¥9,200 million. In addition, an income tax adjustment of ¥183 million was added due to the write-down of deferred tax assets and other factors, expanding the final net loss to ¥9,599 million. The recognition of contingent consideration liabilities related to the Curio acquisition (current liabilities of ¥9,369 million and fixed liabilities of ¥7,880 million) along with long-term borrowings of ¥10,000 million caused the equity ratio to decline from 92.2% to 77.6%, warranting attention to the changing nature of the financial base.

The full-year forecast for FY2027 (ending March 2027) calls for net sales of ¥44,000 million (up 9.1% year on year), an operating loss of ¥2,700 million, and a net loss attributable to owners of parent of ¥6,400 million, projecting a second consecutive year of operating loss despite revenue growth. While recovery is expected in Research Reagents (+12.0%) and Gene Therapy (+19.2%), the probability of achieving this forecast remains uncertain amid a continuing external environment marked by the ongoing impact of U.S. research grant cuts and intensifying competition in China. It should also be noted that after delisting, the frequency and level of detail of earnings disclosures may decrease, making external monitoring more difficult.

Growth Strategy

Taking the opportunity of becoming a wholly-owned subsidiary of Takara Holdings, the company is implementing structural reforms to its revenue structure, aiming to return to profitability through recovery in reagents and gene therapy.

Promoting review of business domains and personnel allocation, efficiency improvements in manufacturing and administrative operations, and strengthening new business development. Announced "Implementation of Structural Reform for Revenue Improvement" on May 13, 2026. Targets compressing the operating loss for FY2027 (ending March 2027) from ¥4,688 million to ¥2,700 million.

Acquisition completed on January 15, 2025 at an acquisition cost of USD 107.4 million. Added high-density, high-resolution spatial analysis reagents utilizing DNA barcode bead technology to the product lineup. Recorded goodwill of ¥6,928 million and technology assets of ¥11,755 million, to be amortized on a straight-line basis over 18 years. Contributes to the plan to raise Research Reagents sales for FY2027 (ending March 2027) from ¥29,197 million to ¥32,705 million (+12.0%).

Construction in progress account increased by ¥7,600 million from ¥19,450 million in the previous fiscal year to ¥27,051 million in the current fiscal year, reflecting ongoing construction of manufacturing facilities. Raised ¥10,000 million in long-term borrowings to continue investment. Recorded an impairment loss of ¥3,876 million related to idle facilities; improving the utilization rate is key to revenue improvement. CDMO Services (Regenerative Medicine-related Products) / Genetic Analysis Services sales are forecast to decline from ¥7,291 million to ¥6,654 million in FY2027 (ending March 2027), indicating limited near-term recovery.

Gene Therapy (Drug Discovery Platform Technology / Ancillary Materials) sales for FY2026 (ending March 2026) declined sharply to ¥2,932 million (down 22.0% year on year), mainly due to a decrease in development projects and changes in development policy among major Japanese pharmaceutical companies. Recovery to ¥3,496 million (+19.2%) is forecast for FY2027 (ending March 2027); acquiring new projects by leveraging the Takara Holdings network is a key challenge.

Last updated: July 17, 2026